‘Biolidics said the ClearEpi NAB Test is intended for the qualitative detection of circulating human IgG antibodies capable of attaching to the Covid-19 spike proteins and preventing binding. "The company wishes to highlight that the ClearEpi NAB Test is intended for use as an aid in identifying individuals with an adaptive immune response to Sars-CoV-2 and should not be used to diagnose or exclude acute Sars-CoV-2 infection," Biolidics added.
‘Biolidics expects the development of the test and the receipt of the CE marking to contribute positively to its revenue for the financial year ending Dec 31, 2021, provided the company is able to successfully market and commercialise the test in the EU.’
Read here (Straits Times, Sept 15, 2021)
